Stryker's Corporate Customers have recorded an advance in their cost of revenue by 7.62 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 10.09 %. During the corresponding time, Stryker Corp recorded a revenue increase by 9.42 % year on year, sequentially revenue grew by 9.45 %. While revenue at the Stryker Corp's corporate clients recorded rose by 7.8 % year on year, sequentially revenue grew by 9.31 %.
Stryker's Customers have recorded an advance in their cost of revenue by 7.62 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 10.09 %, for the same period Stryker Corp recorded revenue increase by 9.42 % year on year, sequentially revenue grew by 9.45 %.
Stryker's Comment on Sales, Marketing and Customers
Stryker operates globally in the healthcare sector, serving over 150 million patients annually. Its products are distributed in approximately 61 countries through subsidiaries, branches, and third-party dealers. The company primarily markets to doctors, hospitals, and healthcare facilities. Stryker's operations are divided into two main business segments: MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, intensive care disposable products, clinical communication and AI-assisted virtual care platform technology, minimally invasive products for stroke and venous thromboembolism treatment, and products for brain and open skull-based surgical procedures. Stryker competes in the Instruments and Endoscopy markets alongside companies such as Zimmer Biomet Holdings, Inc., Medtronic plc, Johnson & Johnson MedTech, ConMed Linvatec, Inc., Karl Storz GmbH & Co., Olympus Optical Co. Ltd., Smith & Nephew plc, Arthrex, Inc., and STERIS plc.
Stryker s Financial Horizon: Navigating Robust Revenues and Rising Costs Stryker Corporation (NYSE: SYK), a prominent player in the medical technology sector, is gearing up to announce its financial results for the fourth quarter and full year 2024 on January 28, 2025. Ahead of the anticipated report, a detailed look at the company s annual performance reveals a landscape of notable growth intertwined with emerging financial pressures. Revenue Growth Amid Rising Costs Over the past year, Stryker has showcased impressive revenue increases, with the company s financial results indicating an 11.92% growth year-on-year, underscoring the firm s resilience and ability to capture market opportunities. Sequentiall...
Stryker, a global leader in medical technology, recently announced the successful completion of the first European operations utilizing the Infinity Total Ankle system with Adaptis and Everlast technology. These groundbreaking procedures were performed by renowned consultant trauma and orthopedic surgeon, David N. Townshend FRCS (Orth), at the North Tyneside General Hospital in the United Kingdom.While Stryker celebrates this milestone achievement, the company is also grappling with certain challenges. In the first quarter of 2024, D and Stryker s Corporate Customers experienced a 6.92% increase in their cost of revenue compared to the previous year. However, sequentially, costs of revenue were reduced by 3....
The globally-renowned medical technology company, Stryker (NYSE:SYK), has announced the rollout of its ground-breaking Gamma4 Hip Fracture Nail System in the majority of European markets. This cutting-edge system, engineered for the treatment of hip and femur fractures, offers surgeons the latest generation of Stryker s intramedullary nail system.The introduction of the Gamma4 System is designed to streamline surgical procedures, melding sophisticated technology with contemporary medical practice. The launch coincides with a significant upswing in Stryker’s financial performance. For instance, Stryker s corporate customers experienced a 12.7% year-on-year surge in the cost of revenue by the close of the fo...
Stryker’s Comment on Sales, Marketing and Customers
Stryker operates globally in the healthcare sector, serving over 150 million patients annually. Its products are distributed in approximately 61 countries through subsidiaries, branches, and third-party dealers. The company primarily markets to doctors, hospitals, and healthcare facilities. Stryker's operations are divided into two main business segments: MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, intensive care disposable products, clinical communication and AI-assisted virtual care platform technology, minimally invasive products for stroke and venous thromboembolism treatment, and products for brain and open skull-based surgical procedures. Stryker competes in the Instruments and Endoscopy markets alongside companies such as Zimmer Biomet Holdings, Inc., Medtronic plc, Johnson & Johnson MedTech, ConMed Linvatec, Inc., Karl Storz GmbH & Co., Olympus Optical Co. Ltd., Smith & Nephew plc, Arthrex, Inc., and STERIS plc.
Sources:
Stryker Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Stryker Corp’s corporate clients.
For your research, we’ve provided 9 tables on Stryker Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
8.12 %
10.21 %